Eloxx Pharmaceuticals To Present at the Cowen and Company 38th Annual Health Care Conference

Published: Mar 06, 2018

Waltham, MA. – March 6, 2018 – Eloxx Pharmaceuticals, Inc. (“Eloxx”), (ELOX) a clinical-stage biopharmaceutical company developing novel read-through drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases, today announced that Chairman and Chief Executive Officer, Robert E. Ward, will present at the Cowen and Company 38th Annual Health Care Conference on Monday, March 12, 2018 at 1:30 p.m. EST at the Boston Marriott Copley Place.

A live audio webcast witll be available on the “Events & Presentations” section of the  Company’s investor website at www.radiuspharm.com, where a replay will also be available following the presentation.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 2,000 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx’s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA. with R&D operations in Rehovot, Israel.

Contact:

Barbara Ryan
203-274-2825
barbarar@eloxxpharma.com

Back to news